Shamez Ladhani Profile picture
Sep 14, 2021 11 tweets 4 min read Read on X
1/ How long do 2 doses of #COVID19 vaccines protect for? Who needs booster vaccinations?

Our team @phe_uk have just published a pre-print on vaccine effectiveness (VE) and duration of protection after 2 doses of Pfizer and AZ vaccines in adults … 🧵

👉 khub.net/documents/1359…
2/ We now have data for ~6 months post-vaccination & compare VE by age, comorbidity & #sarscov2 strain (Alpha/Delta)

We used a test-negative case-control design to estimate VE after 2 doses against PCR-confirmed disease, hospitalisation within 14d of PCR test & death within 28d
3/ In this analysis, 2 million adults (38.7%) had 2x AZ, 1.7 million (31.7%) had 2x Pfizer, 124k (2.4%) had 2x Moderna & 10k (0.2%) had mixed/other

There were 1.5 million cases (544k Alpha, 895k Delta, 37k other/unknown) & 3.8 million negative tests from 3.3 million adults
4/ VE against symptomatic disease peaked in the early weeks after 2nd dose, then fell to 47.3% (95% CI 45.0 to 49.6) by 20+ weeks against the Delta variant for AZ vaccine & 69.7% (95% CI 68.7 to 70.5) for Pfizer vaccine
5/ HOWEVER, there was little waning in protection against hospitalization, with a VE against Delta variant of 77.0% (70.3 to 82.3) beyond 20 weeks post-vaccination for the AZ vaccine & 92.7% (90.3 to 94.6) for Pfizer vaccine.

High protection for both vaccines against death, too
6/ When compared by age, VE against hospitalisation remained high for 20+ weeks. In general, there was more waning in protection against hospitalisation among 65+ compared to 45-64 year-olds.

Note: wide overlapping CI for 40-64y with AZ vaccine at 20+ weeks due to limited data
7/ VE by clinical risk group: very high VE retained for 20+ weeks for both vaccines in adults who were not in a clinical risk group

VE in risk groups started lower & had more waning vs adults not in a risk group, but note wide confidence intervals because of smaller cohorts
8/ Among 40-64-year olds in a clinical risk group, there was some evidence of waning of protection against hospitalization with time since vaccination after 2 doses of AZ vaccine

Virtually no waning of protection against hospitalization for 20+ weeks in healthy 40-63 year-olds
9/ Interestingly, 80+ year-olds receiving Pfizer at shorter interval (<4 weeks) between doses had lower VE compared to an extended interval (≥ 8 weeks) between doses in the latest follow-up periods (>20 weeks after dose 2), although confidence intervals were wide & overlapping
10/ In conclusion, high overall VE is sustained against hospitalisation & death for >5 months post-vaccination

In general, more waning seen with AZ vs. Pfizer, older vs. younger adults and being in a clinical risk group - important info when considering booster prioritisation
11/ Food 4 thought:

👉Could we have waited a little longer before giving boosters? Balance between waning immunity, speed of vaccination, hospital pressures & risk of new variants

👉Although easier to use same vaccines, lower dose +/- variant vaccines might make better boosters

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Shamez Ladhani

Shamez Ladhani Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ShamezLadhani

Jan 30, 2023
1/ Remember all the media coverage of #omicron causing so much severe #COVID19 in young kids?

We extended our @UKHSA #COVID19 deaths surveillance in kids & found:

ONE #COVID19 fatality per MILLION #Omicron infections in children aged <20 yrs …🧵

👉 sciencedirect.com/science/articl…
2/ We assessed all fatalities within 30 days of a positive #SARSCoV2 test in <20 year-olds during Jan-Mar 2022 when national testing was still available. We collected detailed clinical data from multiple sources to ascertain cause of death for each child
3/ During Jan-Mar 2022, there were 46 deaths within 30 days of a positive #SARSCoV2 test & 11 were due to COVID-19

👉All 11 #COVID19 deaths occurred after primary SARS-CoV-2 infection

👉 8/11 (73%) had underlying comorbidities, including 4 with severe neurodisabilities Image
Read 9 tweets
Dec 30, 2022
1/ This is so mportant - thank you @kerpen for tagging me

The US with all its mitigations, vaccine & booster mandates has the same proportion of kids already exposed to #sarscov2 as the UK, which as been accused of “letting the virus rip”

90.3% (US) vs 86.7% (UK)

…🧵
2/ In England, among 1-17 year-olds, we recently reported that by Sep 2022

➡️ 86.2% (95%CrL 81.1-91.6) had infection-induced #SARSCoV2 N antibodies

➡️ 97.2% (95% CrI 93.7%–98.9%) had #SARSCoV2 S-antibodies (infection and/or vaccine)

👉 journalofinfection.com/article/S0163-…
3/ According to US CDC, #SARSCoV2 antibody seroprevalence in 6m-17y by Sep-Oct 2022 was no different:

➡️ 90.3% (95%CI 89.8-90.8) had infection-induced N antibodies

➡️ 95.9% (95%CI 95.5-96.3) had S-antibodies (infection and/or vaccine)

👉 covid.cdc.gov/covid-data-tra…
Read 5 tweets
Dec 28, 2022
1/ Our @UKHSA paper on paediatric #SARSCoV2 antibody prevalence in England is now published

By Sep 2022, 97.2% of 1-17 year-olds had #SARSCoV2 antibodies

Our findings are critical for future #COVID19 vaccine/booster recommendations for kids

…🧵

👉sciencedirect.com/science/articl…
2/ Methods: We used residual samples from kids aged 1–17 years having a blood test as part of their clinical management in 44 hospital trusts in England. Samples were processed using Roche Elecsys assays for i) nucleocapsid (N) antibodies and ii) spike RBD (S) antibodies
3/ The overall national prevalence estimate of #SARSCoV2 antibody seropositivity in 1-17y, weighted by age & NHS region, based on Spike protein (vaccine or infection) increased from

➡️ 48.5% (95% CrI 40.8%–55.1%) during Sep-Oct 2021
to
➡️ 97.2% (95% CrI 93.7%–98.9%) by Sep 2022 Image
Read 8 tweets
Dec 5, 2022
1/ Our latest paper on longitudinal follow-up of teens with long covid (CLoCk) is a game changer:

Different teens report the same post-covid symptoms at 0, 6m & 12m after their #SARSCoV2 PCR , irrespective of whether they tested + or - for the virus

👉 sciencedirect.com/science/articl…
2/ Method: we followed up 11-17y with a PCR-positive #SARSCoV2 test compared with matched PCR-negative controls for 12 months after their test. The final cohort included 2,909 cases and 2,177 controls
3/ We found that teens reporting a symptom at baseline (PCR-testing) improved by 6m, with new teens reporting the same symptoms at 6m, who then improved by 12m, with new kids reporting the same symptoms at 12m and so on …. you catch the drift .. 👇
Read 9 tweets
Nov 18, 2022
1/ It’s really sad that, when we report that a disease (eg. #covid19) is more severe or fatal in kids with underlying conditions (eg neurodisabilities, immunocompromised), this is taken to mean that such kids are less valued

The truth is exactly the opposite…🧵
2/ It is really important that we identify kids at increased risk of severe outcomes after any condition (eg #COVID19) so we can raise awareness among clinicians, parents & policymakers to be extra vigilant & implement additional strategies protect them 👉journals.plos.org/plosmedicine/a…
3/ When kids with severe neurodisabilities were identified as high-risk in the 1st pandemic wave, the UK recommended #COVID19 vaccines for 12+y kids with severe neurodisabilities as soon as vaccines were licensed in adults - way back in Jan 2021 👉 adc.bmj.com/content/106/12…
Read 7 tweets
Nov 17, 2022
Remember that recent US paper on #covid19 vaccination for 5-11y?

We didn’t agree with the conclusions (h/t @ProfAsmaKhalil)

So, we wrote to @NEJM to explain why US data do NOT support BOOSTERS for kids irrespective of their previous infection status

👉 nejm.org/doi/full/10.10… Image
2/ We pointed out that there was very little difference in protection against omicron infection between vaccinated & previously infected 5-11y, while infection plus 2 vaccine doses might provide slightly better protection after 4 months (79.4% vs 62.9%)

👉nejm.org/doi/full/10.10…
3/ We then pointed out that #COVID19 hospitalizations were v low in 5-11y irrespective of vaccination status (0.3-0.5%), although we still aren’t sure how these were calculated because numerator/denominator in their table give lower percentages (0.1%)🤷🏻‍♂️

👉nejm.org/doi/suppl/10.1…
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(